Pharmacokinetics of Caspofungin

Medical University of Lublin33 enrolled

Overview

The objective of this study is to describe the pharmacokinetics of standard doses of caspofungin in critically ill patients.

This is a prospective observational study performed on critically ill patients. Inclusion criteria are: severe sepsis on admission requiring broad-spectrum antibiotics. Both medical and surgical patients will be included. Any type of infections will be included (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes: broad spectrum anti-bacterial antibiotics plus caspofungin (70 mg i.v. on the first day day, and 50 mg i.v. on the consecutive days, once daily. Blood samples (3 mL) will be collected 2, 4, 8,12 and 24 hours after each dose of caspofungin for 3 consecutive days. The standard arterial canula will be used to obtain samples. 30 minutes after each sample collection, blood will be centrifuged for 10 minutes at 3,000 rpms. Subsequently, supernatant will be collected and frozen. Serum caspofungin concentration will be measured with high performance liquid chromatography. Each patient's hemodynamics parameters will be recorded with the use of transpulmonary thermodilution technique (PICCO). Other therapies i.e.: ventilatory support, sedation, an antifungal agent will be given as required.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Septic Shock Fungal Infection Critical Illness

Interventions

CaspofunginDRUG

Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who require ICU treatment due to severe sepsis age * 18-80 years * an eligible consent obtained from the patient or his/her attendant Exclusion Criteria: * allergy to caspofungin * lack of consent to participate in the study * age of patients below 18 or above 80 years

Locations (1)

II Department of Anesthesia and Intensive Care, Medical University of Lublin

Lublin, Poland

Outcomes

Primary Outcomes

Serum concentration of caspofungin

Samples obtain from ICU patients 2, 4, 8 12 and 24hours after each dose of caspofungin for 3 days.

Time frame: 72 hours for each patient from the tigecycline treatment initiation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.